Published in Int J Cancer on February 15, 2011
Updating the natural history of human papillomavirus and anogenital cancers. Vaccine (2012) 1.65
TLR8: the forgotten relative revindicated. Cell Mol Immunol (2012) 1.12
The immune response to papillomavirus during infection persistence and regression. Open Virol J (2012) 1.02
The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med (2013) 1.01
Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. Int J Cancer (2013) 0.96
Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol (2011) 0.93
Evolutionary ecology of human papillomavirus: trade-offs, coexistence, and origins of high-risk and low-risk types. J Infect Dis (2011) 0.89
Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence. Clin Infect Dis (2013) 0.89
The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer. Int J Med Sci (2014) 0.84
Biological and behavioral risks for incident Chlamydia trachomatis infection in a prospective cohort. Obstet Gynecol (2014) 0.83
Integrative analyses reveal novel strategies in HPV11,-16 and -45 early infection. Sci Rep (2012) 0.82
Comparison of the immune microenvironment of the oral cavity and cervix in healthy women. Cytokine (2013) 0.82
Genetic variation in the TLR and NF-κB pathways and cervical and vulvar cancer risk: a population-based case-control study. Int J Cancer (2013) 0.81
Cervical cancer cell supernatants induce a phenotypic switch from U937-derived macrophage-activated M1 state into M2-like suppressor phenotype with change in Toll-like receptor profile. Biomed Res Int (2014) 0.81
Early Defensive Mechanisms against Human Papillomavirus Infection. Clin Vaccine Immunol (2015) 0.78
Biomarkers of oxidant load and type-specific clearance of prevalent oncogenic human papillomavirus infection: markers of immune response? Int J Cancer (2011) 0.78
TLR9 re-expression in cancer cells extends the S-phase and stabilizes p16(INK4a) protein expression. Oncogenesis (2016) 0.78
Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota. Mucosal Immunol (2017) 0.77
Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clin Immunol (2015) 0.77
Polymorphism in the promoter region of the Toll-like receptor 9 gene and cervical human papillomavirus infection. J Gen Virol (2013) 0.77
The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection. Ther Adv Vaccines (2013) 0.77
Evasion of Host Immune Defenses by Human Papillomavirus. Virus Res (2016) 0.77
Differential gene expression between skin and cervix induced by the E7 oncoprotein in a transgenic mouse model. Virology (2012) 0.76
Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response. Int J Cancer (2014) 0.76
Association of toll-like receptor gene polymorphisms and its interaction with HPV infection in determining the susceptibility of cervical cancer in Chinese Han population. Mamm Genome (2017) 0.75
Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study. PLoS One (2017) 0.75
TLR9 gene polymorphism -1486T/C (rs187084) is associated with uterine cervical neoplasm in Mexican female population. J Cancer Res Clin Oncol (2017) 0.75
The Mouse Papillomavirus Infection Model. Viruses (2017) 0.75
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol (2000) 7.78
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol (2003) 3.97
The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr (1998) 3.96
Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol (2004) 3.82
Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A (2004) 3.74
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine (2006) 3.72
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS (2007) 3.14
Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol (2002) 2.86
High-throughput real-time quantitative reverse transcription PCR. Curr Protoc Mol Biol (2006) 2.41
Immune responses to human papillomavirus. Vaccine (2006) 2.37
qPrimerDepot: a primer database for quantitative real time PCR. Nucleic Acids Res (2006) 2.31
RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res (2006) 2.11
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol (2002) 1.88
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Viral recognition by Toll-like receptors. Semin Immunol (2007) 1.68
Immunobiology of HPV and HPV vaccines. Gynecol Oncol (2008) 1.66
Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology (2008) 1.62
Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood (2006) 1.62
Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol (2007) 1.61
Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis (2000) 1.50
Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. J Clin Immunol (2006) 1.48
Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res (2004) 1.43
Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. J Virol (2006) 1.35
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30
Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates. Clin Vaccine Immunol (2007) 1.22
Pleiotropic function of Toll-like receptors. Microbes Infect (2004) 1.21
HPV innate immunity. Front Biosci (2002) 1.21
Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol (1999) 1.18
Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. Appl Environ Microbiol (2007) 1.17
B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol (2005) 1.16
Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer (2009) 1.13
High-risk human papilloma virus infection decreases the frequency of dendritic Langerhans' cells in the human female genital tract. Immunology (2006) 1.09
Validation of reference genes in cervical cell samples from human papillomavirus-infected and -uninfected women for quantitative reverse transcription-PCR assays. Clin Vaccine Immunol (2008) 1.01
Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol (2008) 0.94
The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol (2003) 0.89
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin (2002) 5.56
Aryl-aryl bond formation by transition-metal-catalyzed direct arylation. Chem Rev (2007) 4.69
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med (2003) 3.26
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Regression of low-grade squamous intra-epithelial lesions in young women. Lancet (2004) 2.98
Enantioselective alpha-trifluoromethylation of aldehydes via photoredox organocatalysis. J Am Chem Soc (2009) 2.98
Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol (2006) 2.94
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS (2012) 2.15
A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol (2003) 2.11
Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis (2004) 2.06
Differential effects of ramipril on ambulatory blood pressure in African Americans and Caucasians. Am J Hypertens (2007) 2.06
External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis (2002) 2.05
Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol (2010) 1.94
Factors that influence the rate of epithelial maturation in the cervix in healthy young women. J Adolesc Health (2009) 1.89
Sexual bridging socially and over time: a simulation model exploring the relative effects of mixing and concurrency on viral sexually transmitted infection transmission. Sex Transm Dis (2006) 1.78
A prospective examination of weight gain in hospitalized adolescents with anorexia nervosa on a recommended refeeding protocol. J Adolesc Health (2011) 1.74
Smoking-related cue-induced brain activation in adolescent light smokers. J Adolesc Health (2011) 1.72
Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. AIDS Patient Care STDS (2011) 1.66
How reliable are tests for trachoma?--a latent class approach. Invest Ophthalmol Vis Sci (2011) 1.65
T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis (2005) 1.63
Using qualitative research to inform survey development on nicotine dependence among adolescents. Drug Alcohol Depend (2002) 1.55
A randomized trial of nicotine nasal spray in adolescent smokers. Pediatrics (2008) 1.55
Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One (2010) 1.55
Quasi-experimental designs in practice-based research settings: design and implementation considerations. J Am Board Fam Med (2011) 1.51
Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. J Clin Immunol (2006) 1.48
Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. AIDS (2010) 1.47
Incidence of acute urinary tract infection in young women and use of male condoms with and without nonoxynol-9 spermicides. Epidemiology (2002) 1.47
Association of attitudes and beliefs towards antiretroviral therapy with HIV-seroprevalence in the general population of Kisumu, Kenya. PLoS One (2009) 1.45
An early view of the international Sjögren's syndrome registry. Arthritis Rheum (2009) 1.43
Audio computer-assisted self-interviewing in reproductive health research: reliability assessment among women in Harare, Zimbabwe. Contraception (2006) 1.37
Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr (2010) 1.35
Phosphatidylethanol (PEth) as a biomarker of alcohol consumption in HIV-positive patients in sub-Saharan Africa. Alcohol Clin Exp Res (2011) 1.33
Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescents. AIDS (2003) 1.31
Cotinine levels in relation to smoking behavior and addiction in young adolescent smokers. Nicotine Tob Res (2007) 1.30
Sexual risk behavior among youth with perinatal HIV infection in the United States: predictors and implications for intervention development. Clin Infect Dis (2012) 1.26
Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates. Clin Vaccine Immunol (2007) 1.22
CD8+CD38+ T cells but not HIV type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV+ adolescent population. AIDS Res Hum Retroviruses (2004) 1.19
Sexual seroadaptation: lessons for prevention and sex research from a cohort of HIV-positive men who have sex with men. PLoS One (2010) 1.18
Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. J Infect Dis (2013) 1.17
HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol (2006) 1.15
Withdrawal in adolescent light smokers following 24-hour abstinence. Nicotine Tob Res (2009) 1.15
Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. Clin Diagn Lab Immunol (2004) 1.14
Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer (2009) 1.13
Risks for cervical intraepithelial neoplasia 3 among adolescents and young women with abnormal cytology. Obstet Gynecol (2008) 1.13
Identification of human papillomavirus type 58 lineages and the distribution worldwide. J Infect Dis (2011) 1.13
Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis (2010) 1.11
Human papillomavirus concordance in heterosexual couples. J Adolesc Health (2010) 1.07
Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J Reprod Immunol (2010) 1.07
The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One (2008) 1.06
Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection. Am J Pathol (2010) 1.05
Participation of Asian-American women in cancer chemoprevention research: physician perspectives. Cancer (2005) 1.05
Patterns and predictors of adherence to diaphragm use in a phase III trial in sub-Saharan Africa: a trajectory analysis. J Acquir Immune Defic Syndr (2009) 1.05
Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies. Cytokine (2011) 1.05
Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol (2005) 1.05
Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. Pediatrics (2008) 1.04
American cancer society guideline for the early detection of cervical neoplasia and cancer. J Low Genit Tract Dis (2003) 1.04
Comparison of natural histories of human papillomavirus detected by clinician- and self-sampling. Int J Cancer (2010) 1.04
Nicotine metabolism and addiction among adolescent smokers. Addiction (2012) 1.04
Applications of continuous time hidden Markov models to the study of misclassified disease outcomes. Stat Med (2003) 1.03
Cervical human papillomavirus incidence and persistence in a cohort of HIV-negative women in Zimbabwe. Sex Transm Dis (2009) 1.03
Commentary on Schroder et al. (2003a, 2003b). Ann Behav Med (2005) 1.03
Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02
Validation of reference genes in cervical cell samples from human papillomavirus-infected and -uninfected women for quantitative reverse transcription-PCR assays. Clin Vaccine Immunol (2008) 1.01
Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. HPB (Oxford) (2012) 0.99
Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int J Cancer (2009) 0.98
Participation of Asian-American women in cancer treatment research: a pilot study. J Natl Cancer Inst Monogr (2005) 0.98
Do hospitals that serve a high percentage of Medicaid patients perform well on evidence-based guidelines for colon cancer care? J Health Care Poor Underserved (2013) 0.97
Effect of diaphragm and lubricant gel provision on human papillomavirus infection among women provided with condoms: a randomized controlled trial. Obstet Gynecol (2008) 0.97